Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details)

v3.8.0.1
Summary of Significant Accounting Policies (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Jan. 01, 2016
Dec. 31, 2015
Sep. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
Segment
Sep. 30, 2016
USD ($)
Dec. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Summary of Significant Accounting Policies [Line Items]                  
Provision for inventory obsolescence         $ 5,000 $ 200      
Goodwill, in-process research and development and other intangible assets acquired     $ 2,100,000   2,100,000   $ 2,100,000    
In-process research and development     (648,377)   (648,377)   (644,713)    
Amortization expense     18,023 $ 18,116 53,904 47,337      
Intangible assets, net     714,552   714,552   763,976    
Depreciation expense         22,700 25,300      
Deferred revenue     120,400   120,400   162,400    
Revenue from transfer of intellectual property and other     11,665 18,441 58,819 105,338      
Allowance for doubtful accounts receivable     57,644   57,644   $ 36,268    
Provision for bad debts         78,300 62,500      
Equity-based compensation expense         $ 22,300 34,900      
Number of reportable segments | Segment         2        
Minimum                  
Summary of Significant Accounting Policies [Line Items]                  
Intangible assets, estimated useful lives         3 years        
Maximum                  
Summary of Significant Accounting Policies [Line Items]                  
Intangible assets, estimated useful lives         20 years        
Government Contracts Concentration Risk | Sales Revenue, Net                  
Summary of Significant Accounting Policies [Line Items]                  
Concentration percentage         31.00%        
Government Contracts Concentration Risk | Accounts Receivable                  
Summary of Significant Accounting Policies [Line Items]                  
Concentration percentage         22.00%   22.90%    
Software                  
Summary of Significant Accounting Policies [Line Items]                  
Property, plant and equipment, estimated useful lives         3 years        
Machinery, Medical and Other Equipment | Minimum                  
Summary of Significant Accounting Policies [Line Items]                  
Property, plant and equipment, estimated useful lives         5 years        
Machinery, Medical and Other Equipment | Maximum                  
Summary of Significant Accounting Policies [Line Items]                  
Property, plant and equipment, estimated useful lives         8 years        
Furniture and Fixtures | Minimum                  
Summary of Significant Accounting Policies [Line Items]                  
Property, plant and equipment, estimated useful lives         5 years        
Furniture and Fixtures | Maximum                  
Summary of Significant Accounting Policies [Line Items]                  
Property, plant and equipment, estimated useful lives         12 years        
Buildings and Improvements | Minimum                  
Summary of Significant Accounting Policies [Line Items]                  
Property, plant and equipment, estimated useful lives         10 years        
Buildings and Improvements | Maximum                  
Summary of Significant Accounting Policies [Line Items]                  
Property, plant and equipment, estimated useful lives         40 years        
Automobiles and Aircraft | Minimum                  
Summary of Significant Accounting Policies [Line Items]                  
Property, plant and equipment, estimated useful lives         3 years        
Automobiles and Aircraft | Maximum                  
Summary of Significant Accounting Policies [Line Items]                  
Property, plant and equipment, estimated useful lives         15 years        
Collaborative Arrangement, Product | Pfizer                  
Summary of Significant Accounting Policies [Line Items]                  
Deferred revenue     112,300   $ 112,300        
Revenue from transfer of intellectual property and other     $ 11,200 $ 17,700 $ 46,500 $ 53,000      
Self-Pay | Accounts Receivable                  
Summary of Significant Accounting Policies [Line Items]                  
Concentration percentage         2.40%   4.10%    
Internal Revenue Service (IRS)                  
Summary of Significant Accounting Policies [Line Items]                  
Corporate income tax rate     35.00%   35.00%        
Israel Tax Authority                  
Summary of Significant Accounting Policies [Line Items]                  
Corporate income tax rate 24.00% 25.00%     23.00%        
Scenario, Adjustment                  
Summary of Significant Accounting Policies [Line Items]                  
In-process research and development               $ 187,600  
Intangible assets, net               $ 187,600  
In-process Research and Development                  
Summary of Significant Accounting Policies [Line Items]                  
Intangible assets, estimated useful lives           12 years      
Rayaldee                  
Summary of Significant Accounting Policies [Line Items]                  
Deferred revenue     $ 6,500   $ 6,500        
Accounting Standards Update 2016-09, Excess Tax Benefit Component                  
Summary of Significant Accounting Policies [Line Items]                  
Deferred tax asset                 $ 32,500
Accumulated Deficit | Accounting Standards Update 2016-09, Excess Tax Benefit Component                  
Summary of Significant Accounting Policies [Line Items]                  
Cumulative effect of new accounting update                 $ (32,500)